Idexx Laboratories stock kpis
Want to see IDXX full AI Analyst Report?
Operating Income by Segment
Idexx Laboratories reported operating income by segment of $261.69M in Q4 2024, down 13.9% from Q3 2024 and up 6.7% year over year. The highest value was $303.89M in Q3 2024.
Shows operating profit and margins for each segment, indicating where Idexx is most efficient and where higher R&D, sales or admin costs are weighing on returns. Helps spot which businesses are contributing real profits versus those that may require heavy investment to scale.
IDEXX Laboratories' CAG segment shows consistent growth, reflecting strong execution and innovation adoption, as highlighted by recent earnings. Despite fluctuations in other segments, CAG's robust performance aligns with a 7.5% increase in diagnostic recurring revenues and record instrument placements. However, challenges like declining U.S. clinical visits and Rapid assay revenue dips could impact future growth. The company's optimistic outlook, with increased revenue and EPS projections, underscores confidence in overcoming these hurdles and sustaining momentum, particularly in international markets where growth remains strong.
No longer reported by the company (last reported Q4 2024)
IDXX Operating Income by Segment
| Period | Other | CAG | Water | LPD | Total |
|---|---|---|---|---|---|
| Q4 2024Dec 31, 2024 | -$2.77M | $240.09M | $20.99M | $3.38M | $261.69M |
| Q3 2024Sep 30, 2024 | $2.31M | $277.08M | $23.61M | $889.00K | $303.89M |
| Q2 2024Jun 30, 2024 | $248.00K | $241.55M | $20.50M | $1.50M | $263.80M |
| Q1 2024Mar 31, 2024 | -$1.03M | $279.70M | $19.43M | $866.00K | $298.96M |
| Q4 2023Dec 31, 2023 | $1.65M | $222.12M | $17.22M | $4.31M | $245.30M |
| Q3 2023Sep 30, 2023 | -$808.00K | $253.36M | $20.33M | $2.40M | $275.28M |
| Q2 2023Jun 30, 2023 | -$1.14M | $275.51M | $19.82M | $1.95M | $296.14M |
| Q1 2023Mar 31, 2023 | $370.00K | $261.75M | $16.97M | $1.31M | $280.40M |
| Q4 2022Dec 31, 2022 | $3.30M | $199.84M | $18.02M | $5.36M | $226.53M |
| Q3 2022Sep 30, 2022 | -$1.03M | $221.45M | $19.92M | $4.48M | $244.83M |
| Q2 2022Jun 30, 2022 | $1.39M | $156.53M | $17.92M | $3.23M | $179.07M |
| Q1 2022Mar 31, 2022 | $1.83M | $223.13M | $16.65M | $6.74M | $248.34M |
| Q4 2021Dec 31, 2021 | $4.86M | $174.13M | $15.85M | $4.36M | $199.19M |
| Q3 2021Sep 30, 2021 | $2.82M | $201.95M | $17.60M | $3.60M | $225.96M |
| Q2 2021Jun 30, 2021 | $422.00K | $234.74M | $17.23M | $6.87M | $259.25M |
| Q1 2021Mar 31, 2021 | $5.83M | $213.21M | $14.77M | $13.81M | $247.62M |
| Q4 2020Dec 31, 2020 | $9.20M | $148.82M | $15.48M | $11.59M | $185.09M |
| Q3 2020Sep 30, 2020 | $6.67M | $139.43M | $15.24M | $10.51M | $171.86M |
| Q2 2020Jun 30, 2020 | $4.77M | $167.97M | $12.26M | $8.25M | $193.25M |
| Q1 2020Mar 31, 2020 | $121.00K | $118.66M | $15.88M | $9.66M | $144.32M |

